Pharmed is one of the fastest-growing pharmaceutical companies in India. For over 7 decades, Pharmed has served the healthcare industry with high-quality, innovative and evidence-based nutraceutical and pharmaceutical products, which helped millions of users for a better and enriched quality of life, healthier than before. Not only that these products have also earned acceptance and acclaim of the medical fraternity, quite often opening the doors of new disease management strategies.

Its core strength lies in identifying, researching, and creating a unique lifestyle modifying nutraceutical and therapeutic range of products. Pharmed is a name to reckon with in the therapy areas of women's health; reproductive health; joint, bone and tendon health; pain management; cardiodiabetic health; ear, nose, throat health; urogenital health; digestive health; immune health and general health.

Credit for this success can be imparted to our innovative formulations, product development and marketing, efficient distribution, and logistic channels, partnerships with other innovators, a large and efficient field force, and our access to doctors across various specialties in India through three different marketing divisions, Pharma, ACE, and Synergy.

Innovations in Pharmed

Pharmed has always sought after innovative formulations which can address the therapy gaps effectively. To that end, over the years, as we moved on, we have created a trail of evidence-based innovations that can cater to both the doctors' and patients' needs. Some such examples follow

_________________________________________________________________________________________________________________________________________________________________________________________

During the year under review, your Company recorded consolidated revenue of Rs. 37057 lakhs as against Rs. 30188 lakhs in the previous year from operations. After accounting for Sales Returns and Trade Discounts, the net revenue is Rs. 35019 lakhs as against Rs. 28194 lakhs in the previous year. The Companys Consolidated Net Profit for the year stood at Rs. 4231 lakhs, as against Rs. 3738 lakhs in the previous year. Companys affairs and business prospects.

The Companys performance during the year under review has been satisfactory. It constantly monitors its performance in the Pharma Industry in terms of its rankings in the Indian Pharma Market and covered market through Research Agencies such as C MARC and IQVIA and takes initiatives on new products.

The Board recommends a dividend at Rs. 3.50 on each fully paid equity share of face value Rs. 2/- amounting to Rs. 1,50,71,700/-.